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http://www.biomedcentral.com/1471-2474/15/341RESEARCH ARTICLE Open AccessSteroid injections added to the usual treatment
of lumbar radicular syndrome: a pragmatic
randomized controlled trial in general practice
Antje Spijker-Huiges*, Jan C Winters, Marten van Wijhe and Klaas GroenierAbstract
Background: Lumbosacral radicular syndrome (LRS) is a self-limiting, benign, painful and impairing condition
caused by lumbar disc herniation and inflammatory processes around the nerve root. Segmental epidural steroid
injections (SESIs) are helpful to reduce radicular pain on a short-term basis. It is unknown whether SESIs are an
effective addition to usual pain treatment of LRS in general practice. In our study, we assessed the effectiveness of
SESIs on pain and disability as an addition to usual care for acute LRS in general practice.
Methods: A pragmatic, single-blinded, randomized controlled trial in Dutch general practice was conducted.
Circumstances of daily practice were closely followed. Care as usual (CAU) was compared to care as usual combined
with an additional SESI in 63 patients in the acute phase of LRS. To detect a minimal clinically important difference
of 1.2 points on a numerical rating scale for back pain and a common within-group standard deviation of 1.7 with
a two-tailed alpha of 0.05 and a power of 0.80, we needed 33 subjects in each group. Statistical analysis was carried
out using mixed models.
Results: A small significant effect in favour of the intervention, corrected for age, sex and baseline values, was
found for back pain, impairment and Roland-Morris disability score. The differences, though statistically significant,
were too small to be considered clinically relevant. Patients from the intervention group were significantly more
satisfied with the received treatment than patients from the control group.
Conclusion: We found a small, statistically significant, but not clinically relevant positive effect of SESIs on back
pain, impairment and disability in acute LRS. We do not recommend implementing SESIs as an additional regular
treatment option in general practice.
Keywords: Lumbosacral radicular syndrome, Sciatica, General practice, Pain treatment, Epidural injectionsBackground
Lumbosacral radicular syndrome (LRS) is defined as
pain, radiating from the back into the leg, (“sciatica”) in
combination with Lasègue’s sign and/or neurological
symptoms originating from a single nerve root. In the
Netherlands, LRS is treated by general practitioners (GPs)
who adhere to the Dutch College of General Practitioner’s
Guideline on LRS. According to this guideline, treatment
of LRS consists of pain treatment by taking analgesics as
needed, and maintaining normal daily activities as much
as possible. The prognosis of LRS is favourable: within* Correspondence: a.spijker-huiges@umcg.nl
Department of General Practice, University Medical Centre Groningen,
Postbus 196, FA20, 9700 AD Groningen, The Netherlands
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article, unless otherwise stated.eight weeks, 80% of patients have reached bearable pain
levels and resumed their work [1]. Some patients, how-
ever, do not adequately respond to conservative therapy
during and after this period [2]. In 25% of patients, radicu-
lar pain becomes chronic [1]. Since there are few effective
and evidence-based conservative pain treatments for LRS,
caring for these patients can be difficult for GPs [2,3].
LRS is most commonly caused by protrusion of a lumbar
intervertebral disc, which results in an inflammatory
response around the nerve root [1,4]. This inflammatory
process is the cause of the radicular pain, rather than
mechanical compression [5-8]. Local anti-inflammatory
drugs may lessen inflammation and pain, making it easier
for patients to profit from the favourable prognosis.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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nerve root blocks (SNRBs) are examples of local anti-
inflammatory treatment. SESIs are not recommended in
the Dutch guidelines for general practitioners, but still the
intervention is applied as a pain treatment for LRS in the
Netherlands.
Efficacy of SESIs in LRS is controversial. Some studies
are underpowered, others lack methodological quality to
justify definite conclusions [2,9-12]. In trials that included
patients in the acute phase of well-defined radicular syn-
drome (“sciatica”), SESIs turned out to be more effective
than placebo in reducing pain and hastening return to
normal daily activities [2,5,8,13-22].
Since patients in the acute phase of LRS are cared for
by GPs, SESIs are a possibly useful treatment option in
general practice. Most RCTs, however, have been con-
ducted to assess efficacy rather than effectiveness (i.e.
placebo-controlled double blinded trials rather than prag-
matic trials), in specialist practice, in heterogeneous
patient groups, with a short-term follow-up and using a
single measuring moment. To our knowledge, no study
has assessed effectiveness in general practice, with mul-
tiple measuring points and a long term follow-up, in a
homogeneous patient group. We assessed the effective-
ness of adding SESIs to usual pain treatment for patients
with acute LRS in general practice, by means of a prag-
matic randomized controlled trial measuring pain, disabil-
ity and recovery in acute LRS patients with profound
sciatica.
Methods
Our trial took place in and around the city of Groningen,
the Netherlands, in 41 general practices with 76 participating
GPs. Patients were recruited between January 1st 2005 and
December 31st 2007 and followed for one year. This study
was approved by the Medical-Ethical Committee of the Uni-
versity Medical Center Groningen in 2005, code 2005/154,
and was registered in the Dutch trial register as SLURP, code
NTR342. This study was funded by the UMCG, there was
no additional funding from external sources.
Our research question calls for a pragmatic study
design, which demands that real life conditions are
followed as closely as possible. Usual care was therefore
not standardized but defined as the treatment decided on
by the patients and their GPs. Since Dutch GPs generally
adhere to the Dutch College of General Practitioner’s
guidelines, usual care consisted of advice and analgesic
medication and/or referral as needed [1,23]. The GPs’
diagnosis of LRS was not evaluated by further specialist
physical examination, except to determine the level at
which the SESI was to be administered. Patients and care-
givers were not blinded.
Inclusion criteria were a diagnosis of LRS established
by the GP, complaints of LRS for at least two weeks andno more than four weeks duration and patient age between
18 and 60 years. The upper age limit of 60 was chosen
because complications of epidural injections are more
common in the over 60 age group, due to osteoporosis.
Exclusion criteria were a history of spinal surgery or spinal
trauma, maintenance therapy with corticosteroids or anti-
coagulants, bleeding disorder, cauda equina syndrome, a
body mass index of more than 35, inadequate mastery of
the Dutch language, allergy to corticosteroids, pregnancy
or an active wish to become pregnant, breastfeeding and
mental disability. Patients with insulin-dependent diabetes
mellitus were not excluded but instructed to measure their
serum glucose levels regularly in the 48 hours after the
intervention.
Patients in whom the GP established the diagnosis of
LRS were given written information on the study, a base-
line symptom questionnaire and an informed consent
form. Patients were asked to complete the questionnaire
and the informed consent form and send them to the
research centre. Upon receiving this information, subjects
were contacted by the primary researcher to check inclu-
sion and exclusion criteria with a protocolled inclusion
form. In the absence of exclusion criteria, the inclusion
form was completed.
Randomization was performed by an independent
colleague with no further involvement in the study. Pre-
prepared, sequentially numbered, opaque, sealed enve-
lopes containing stickers labelled either “SESI” or “CAU”,
balanced after 40 assignments, were used. Upon random-
isation, the consecutive envelope was opened and the
sticker with the allocated treatment was fixed on the
completed inclusion form. Inclusion forms, containing
personal patient information, were coded and kept separ-
ately from follow-up questionnaires. To keep the primary
researcher blinded until after the final analysis of the
results, follow-up questionnaires were provided with the
same codes but contained no personal patient information.
Patients allocated to the intervention group were
presented to the department of anaesthesiology of the
University Medical Centre Groningen (UMCG). SESIs
were administered by a non-involved anaesthesiologist
within 48 hours after randomisation. SESIs consisted
of 80 milligrams of triamcinolone in 10 millilitres of
normal saline and were administered using a lumbar
translaminar approach without additional imaging, one
level above the presumed LRS in either sitting or lateral
position. The skin was anaesthetised with lidocaine, but
no local anaesthetics were injected epidurally to avoid
problems with mobility and bladder emptying. After the
injection, patients were referred back to their GPs for
further usual care. When a patient was randomized to
the CAU-group the GP provided usual care from the
start. The translaminar injection technique without add-
itional imaging, rather than a transforaminal approach
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anaesthetics, was chosen because of the pragmatic study
design - given the shorter waiting time and better acces-
sibility, the intervention would be applied this way in
normal practice as well.
Follow-up in both groups was performed using postal
questionnaires regarding pain, disability, and satisfaction
with treatment, measured at 2, 4, 6, 13, 26 and 52 weeks
after the start of the treatment. The 24-point Roland-
Morris Disability Questionnaire (RMDQ) was used for
measuring disability [24,25]. For measuring pain and
self-perceived impairment, a numeric rating scale (NRS)
from 0 to 10 was used, where 0 meant no pain/impair-
ment and 10 meant the worst pain/impairment imagin-
able. For measuring satisfaction with treatment, weFigure 1 CONSORT population flow schedule.asked patients to grade their treatment on a scale from 0
to 10, where 0 meant very poor and 10 meant excellent.
All variables were measured at every time point. As min-
imal clinically important differences in the interpretation
of the results, a reduction of 30% from baseline was used
for the RMDQ-score and 2.0 was used for the NRS pain
and impairment scores [24-28].
Power calculations were based on the NRS back pain
score at four weeks from the start of the treatment. A dif-
ference in NRS back pain score of 1,2 - 2,0 is considered
clinically relevant in primary care attendants with low
back pain [29-32]. To minimize the risk of underpowering
our study, an MCID of 1.2 was used for the sample size
calculations. The mean standard deviation of VAS scores
in patients with moderate pain is approximately 1,7 [33].
Table 1 Mean RMDQ and NRS scores of study participants for every measuring moment in the follow-up period
Follow-up time (weeks) 0 2 4 6 13 26 52
RMDQ score
Intervention group mean (SD) 16.5 (4.2) 10.7 (7.1) 8.9 (6.8) 8.0 (6.8) 5.3 (5.9) 3.0 (4.5) 2.3 (3.7)
Control group mean (SD) 14.5 (6.1) 12.3 (6.1) 10.5 (7.0) 8.1 (6.3) 7.6 (6.3) 5.4 (6.5) 4.1 (6.2)
NRS back pain
Intervention group mean (SD) 6.2 (2.6) 3.3 (2.9) 3.3 (3.0) 2.5 (2.6) 2.1 (2.5) 1.9 (2.5) 1.3 (1.9)
Control group mean (SD) 4.5 (2.7) 4.1 (3.0) 3.6 (2.7) 2.8 (2.3) 3.0 (3.0) 2.0 (2.4) 2.0 (2.9)
NRS leg pain
Intervention group mean (SD) 7.8 (1.7) 4.2 (3.1) 3.8 (3.3) 2.6 (2.5) 1.6 (2.5) 1.6 (2.4) 1.0 (2.0)
Control group mean (SD) 6.4 (2.3) 4.7 (3.1) 3.9 (2.8) 2.9 (2.5) 2.7 (2.8) 1.9 (2.5) 1.4 (2.2)
NRS pain during day
Intervention group mean (SD) 7.7 (1.6) 4.9 (3.1) 4.5 (3.2) 3.1 (2.7) 2.4 (2.7) 2.2 (2.6) 1.2 (2.0)
Control group mean (SD) 6.2 (2.1) 5.1 (2.8) 4.2 (2.6) 3.3 (2.4) 3.1 (2.9) 2.2 (2.3) 2.2 (3.0)
NRS pain during night
Intervention group mean (SD) 6.4 (2.6) 3.6 (3.2) 3.7 (3.0) 2.5 (2.5) 1.7 (2.6) 1.8 (2.3) 0.8 (1.7)
Control group mean (SD) 5.7 (2.7) 4.3 (3.0) 3.0 (2.8) 2.6 (2.5) 2.6 (2.9) 1.9 (2.5) 1.8 (2.9)
NRS total pain
Intervention group mean (SD) 7.7 (1.2) 5.0 (2.9) 4.2 (3.0) 3.3 (2.5) 2.5 (2.5) 2.3 (2.5) 1.3 (2.0)
Control group mean (SD) 6.9 (1.7) 5.3 (2.6) 4.5 (2.8) 3.7 (2.5) 3.2 (2.8) 2.3 (2.4) 2.1 (3.0)
NRS impairment
Intervention group mean (SD) 7.8 (1.6) 5.2 (3.2) 4.0 (3.1) 3.0 (2.8) 2.6 (2.9) 1.7 (2.2) 1.0 (1.6)
Control group mean (SD) 6.7 (2.2) 5.2 (2.8) 4.7 (2.8) 3.3 (2.9) 3.2 (2.9) 2.1 (2.3) 1.9 (2.6)
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standard deviation of 1.7 with a two-tailed alpha of 0.05
and a power of 0.80, we needed 33 subjects in each group.
To compensate for anticipated lost to follow-up, we
intended to include 40 subjects in each group.
This study was performed to achieve two goals. The
first goal of the study was to test the difference over time
between the means of the two treatments. The second
goal of the study was to estimate the differences between
the means of the two treatments at every time point of
measurement. On average, a study of this design wouldTable 2 Estimated differences between group means
Variable Estimated difference Sta
RMDQ-score 2,5004
NRS back pain 1,1165
NRS leg pain 0,6717
NRS pain during the day 0,6563
NRS pain during the night 0,5285
NRS total pain 0,6890
NRS impairment 1,0254
The differences between group means calculated by the mixed models analysis, ov
repeated measures regression analysis, differences between groups are calculated b
values in the random population. We found significant differences between group
impairment. These differences are statistically significant but too small to be considenable us to report the mean difference with a precision
(95.0% confidence level) of plus/minus 0.84 points.
All analyses were performed using an intention-to-treat
basis. Mixed model regression analysis was performed
using SAS 9.2 PROC MIXED. No data imputation is
necessary using this model [34]. Patients were a random
factor in the model and treatment a fixed factor. For every
outcome variable, treatment and time of measurement as
independent variables were tested with sex, age and
baseline-values as covariates to account for non-balance
in the randomization.ndard error P |t| 95% CI - 95% CI +
1,0435 0,0173 0,4551 4,5456
0,4389 0,0115 0,2562 1,9767
0,5100 0,1890 −0,3279 1,6713
0,5186 0,2068 −0,3601 1,6727
0,4741 0,2659 −0,4007 1,4577
0,4729 0,1463 −0,2378 1,6158
0,4867 0,0361 0,0714 1,9793
er the entire course of the study period using linear regression. In this
ased on the study outcomes, corrected for baseline values, to estimate true
means for RMDQ-score, NRS back pain score and NRS score for self-perceived
ered clinically relevant.
Figure 2 (See legend on next page.)
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Figure 2 A–G: results of the mixed model analysis for pain, impairment and Roland-Morris disability scores. When corrected for baseline
values, there is a significant effect of the intervention on the RMDQ score and on the NRS scores for back pain and self-perceived impairment
(the curve for the intervention group ‘lies below’ the curve for the control group). The effects are statistically significant but too small to be
considered clinically relevant. Differences between groups remain constant over the entire study period (the two curves are parallel).
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Eighty-four patients were presented to us by their GPs, of
whom 73 patients were eligible and included in the study.
A flow schedule is presented in Figure 1. Ten randomized
patients were not included in the analysis. Of these, seven
subjects ended their participation shortly after enrollment
and three subjects did not send back any questionnaires
despite repeated requests. Of one subject the follow-up
was incomplete. She died during the study period due to
Burkitt lymphoma, which initially caused radicular pain.
The subjects lost to follow-up did not differ signifi-
cantly in sex, age, randomization group or baseline
values from the 63 subjects who were included in the
analysis. Of these 63 subjects, 30 were men. The mean
age of the study participants at the time of the inclusion
was 43,7 years (SD 9,8). The intervention group did not
differ significantly from the control group in age or
distribution of the sexes.
For the 63 study participants, we sent out 441 question-
naires, of which 408 (92,5%) were returned. Means and
standard deviations of all variables in both groups for every
time point of measurement are presented in Table 1. The
intervention group differed significantly from the control
group in all baseline values except for leg pain. In the
mixed models regression analysis, these differences were
corrected for by including the baseline values as a covari-
ate. In Table 2 and in Figure 2A-G, the results of the mixed
models regression analysis are shown. Both groups experi-
ence a significant decline over time for all symptoms. The
intervention group experienced significantly less symptoms
than the control group for the RMDQ-score (p = 0,0173),
the NRS back pain score (p = 0,0115) and the NRS score
for self-perceived impairment (p = 0,0361). These differ-
ences between the groups remained constant during the
whole follow-up period. In Figure 2A-B, the courses over
time of all variables for the entire study period are shown
graphically.
Finally, we found a significant difference in mean patient
satisfaction between the two groups. The intervention
group rated their treatment 9,0 on a 0 to 10 scale, and the
control group rated their treatment 7,2 on a 0 to 10 scale
(p = 0,006). No complications or adverse effects of the
intervention were reported.
Discussion
In this study, SESIs yielded a significant overall effect on
RMDQ score, back pain, and self-perceived impairment as
an additional treatment for LRS in a pragmatic generalpractice setting. Small differences between pain severity
scores and other outcomes, however, may be statisti-
cally significant but clinically trivial. As differences of
1.2 – 2.0 on the NRS and a 30% reduction from base-
line (which amounts to 4.5 points in our study) in
RMDQ score can be considered clinically important to
patients, the effects of our intervention are too small to
be relevant [24-32].
The intervention group was significantly more satisfied
with their treatment than the control group, rating a mean
of 9.0 versus 7.2 on a 0 to 10 scale (p = 0,006). As no clin-
ically relevant effect was yielded in our study, the more
positive evaluation of the intervention by patients should
most probably be attributed to the effect of receiving extra
attention and care.
Our study is the first pragmatic trial undertaken in gen-
eral practice, where most patients with LRS are seen and
treated in an early stage. It is one of the few studies aimed
to assess effectiveness rather than efficacy of SESIs. To
our knowledge this has been done only once before, 15
years ago and in a hospital setting [22]. Outcomes of this
study suggested that adding SESIs as a first-line treatment
to rest and a nonsteroidal antiinflammatory drug for LRS
resulted in additional costs and no gain in efficacy. Our
study is the first to evaluate the effect of SESIs on LRS
with mixed models multiple regression analysis, which
enabled us to assess the effect of this intervention over the
whole course of the follow-up time rather than evaluating
its effect on a single moment. Whereas most trials in this
field are underpowered, we included enough patients to
yield a statistically significant effect, although it is still a
small patient population.
This study has some possible limitations. One is the fact
that the intervention group unfortunately differed signifi-
cantly from the control group in baseline values. Since
randomization was adequately performed, we have no
explanation for these differences. In the mixed model
regression analysis the baseline differences were corrected
for by including the baseline values as a covariate. Baseline
differences between groups do, however, raise questions
about whether those groups are truly comparable. The
MCIDs of measuring instruments may vary between
categories of baseline severity in symptoms. According to
the literature, comparing our groups was allowed [28,33].
We are therefore convinced that the difference in baseline
values between our study groups are not a problem for
the analyses and the ultimate interpretation of our trial
results.
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score would have been a more appropriate primary out-
come measure than the NRS back pain score. We chose
back pain for calculating our sample sizes because the
MCID of the NRS back pain score is extensively used and
well described in primary care back pain patients
[24,29,30,32,33]. The RMDQ, however, is more responsive
in sciatica and might in retrospect have been a better
choice as primary outcome measure [24,25,28]. Consider-
ing the outcomes of the RMDQ scores, we can state that
our trial would not have been underpowered had we
chosen the RMDQ for calculating the sample sizes.
No adverse effects of our intervention were reported by
our subjects. One of the subjects, however, died during our
study period due to Burkitt lymphoma, which initially
caused radicular pain. Epidural steroids are known to relief
symptoms of spinal cord compression caused by tumors or
metastases [35]. It is conceivable that administering epidural
steroids to a patient whose radicular complaints are caused
by cancer, delays diagnosis and treatment. To our know-
ledge, no reports about this problem have been published.
Conclusions
Placebo-controlled double blinded randomized trials
have yielded positive results for the efficacy as a pain
treatment of SESIs on LRS. Our study shows that the
intervention has a significant beneficial effect as an add-
itional treatment in general practice as well. This effect
however, is too small to be considered clinically relevant
to patients. Although our patient sample was small, we
do not recommend that administering SESIs for the pain
treatment of LRS be implemented as a regular interven-
tion in general practice. Further research should be
aimed at adequately treating pain in patients with acute
LRS with other interventions.
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